newsfilter
← Latest News
Business Wire·

iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

Phase 1/2 dosing completed across all dose cohorts; participant evaluations ongoing Preliminary safety observations show ECUR-506 was generally well tolerated, with no unexpected treatment-related safety events